Radiology and Oncology最新文献

{"title":"Association between <i>PIK3CA</i> activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy.","authors":"Domen Ribnikar,&nbsp;Valentina Jeric Horvat,&nbsp;Ivica Ratosa,&nbsp;Zachary W Veitch,&nbsp;Biljana Grcar Kuzmanov,&nbsp;Srdjan Novakovic,&nbsp;Erik Langerholc,&nbsp;Eitan Amir,&nbsp;Bostjan Seruga","doi":"10.2478/raon-2023-0027","DOIUrl":"https://doi.org/10.2478/raon-2023-0027","url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to evaluate the independent prognostic role of <i>PIK3CA</i> activating mutations and an association between <i>PIK3CA</i> activating mutations and efficacy of adjuvant endocrine therapy (ET) in patients with operable invasive lobular carcinoma (ILC).</p><p><strong>Patients and methods: </strong>A single institution study of patients with early-stage ILC treated between 2003 and 2008 was performed. Clinicopathological parameters, systemic therapy exposure and outcomes (distant metastasis-free survival [DMFS] and overall survival [OS]) were collected based on presence or absence of PIK3CA activating mutation in the primary tumor determined using a quantitative polymerase chain reaction (PCR)-based assay. An association between PIK3CA mutation status and prognosis in all patient cohort was analyzed by Kaplan-Meier survival analysis, whereas an association between PIK3CA mutation and ET was analyzed in estrogen receptors (ER) and/or progesterone receptors (PR)-positive group of our patients by the Cox proportional hazards model.</p><p><strong>Results: </strong>Median age at diagnosis of all patients was 62.8 years and median follow-up time was 10.8 years. Among 365 patients, PIK3CA activating mutations were identified in 45%. PIK3CA activating mutations were not associated with differential DMFS and OS (p = 0.36 and p = 0.42, respectively). In patients with PIK3CA mutation each year of tamoxifen (TAM) or aromatase inhibitor (AI) decreased the risk of death by 27% and 21% in comparison to no ET, respectively. The type and duration of ET did not have significant impact on DMFS, however longer duration of ET had a favourable impact on OS.</p><p><strong>Conclusions: </strong>PIK3CA activating mutations are not associated with an impact on DMFS and OS in early-stage ILC. Patients with PIK3CA mutation had a statistically significantly decreased risk of death irrespective of whether they received TAM or an AI.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"220-228"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subpleural fibrotic interstitial lung abnormalities are implicated in non-small cell lung cancer radiotherapy outcomes.","authors":"Makoto Ito,&nbsp;Takuma Katano,&nbsp;Hiroaki Okada,&nbsp;Ami Sakuragi,&nbsp;Yoshitaka Minami,&nbsp;Souichiro Abe,&nbsp;Sou Adachi,&nbsp;Yukihiko Oshima,&nbsp;Wataru Ohashi,&nbsp;Akihito Kubo,&nbsp;Takayuki Fukui,&nbsp;Satoru Ito,&nbsp;Kojiro Suzuki","doi":"10.2478/raon-2023-0018","DOIUrl":"https://doi.org/10.2478/raon-2023-0018","url":null,"abstract":"<p><strong>Background: </strong>The relationship between interstitial lung abnormalities (ILAs) and the outcomes of lung cancer radiotherapy is unclear. This study investigated whether specific ILA subtypes are risk factors for radiation pneumonitis (RP).</p><p><strong>Patients and methods: </strong>This retrospective study analysed patients with non-small cell lung cancer treated with radical-intent or salvage radiotherapy. Patients were categorised into normal (no abnormalities), ILA, and interstitial lung disease (ILD) groups. The ILA group was further subclassified into non-subpleural (NS), subpleural non-fibrotic (SNF), and subpleural fibrotic (SF) types. The Kaplan-Meier and Cox regression methods were used to determine RP and survival rates and compare these outcomes between groups, respectively.</p><p><strong>Results: </strong>Overall, 175 patients (normal, n = 105; ILA-NS, n = 5; ILA-SNF, n = 28; ILA-SF, n = 31; ILD, n = 6) were enrolled. Grade ≥2 RP was observed in 71 (41%) patients. ILAs (hazard ratio [HR]: 2.33, p = 0.008), intensity-modulated radiotherapy (HR: 0.38, p = 0.03), and lung volume receiving 20 Gy (HR: 54.8, p = 0.03) contributed to the cumulative incidence of RP. Eight patients with grade 5 RP were in the ILA group, seven of whom had ILA-SF. Among radically treated patients, the ILA group had worse 2-year overall survival (OS) than the normal group (35.3% vs 54.6%, p = 0.005). Multivariate analysis revealed that the ILA-SF group contributed to poor OS (HR: 3.07, p =0.02).</p><p><strong>Conclusions: </strong>ILAs, particularly ILA-SF, may be important risk factors for RP, which can worsen prognosis. These findings may aid in making decisions regarding radiotherapy.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"229-238"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10082202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive functioning in a cohort of high-grade glioma patients.","authors":"Andreja Cirila Skufca Smrdel,&nbsp;Anja Podlesek,&nbsp;Marija Skoblar Vidmar,&nbsp;Jana Markovic,&nbsp;Jana Jereb,&nbsp;Manja Kuzma Okorn,&nbsp;Uros Smrdel","doi":"10.2478/raon-2023-0009","DOIUrl":"https://doi.org/10.2478/raon-2023-0009","url":null,"abstract":"<p><strong>Background: </strong>High grade gliomas are associated with cognitive problems. The aim of the study was to investigate cognitive functioning in a cohort of patients with high grade glioma, according to isocitrate dehydrogenase (IDH) and methyl guanine methyl transferase (MGMT) status and other clinical characteristics.</p><p><strong>Patients and methods: </strong>The patients with the high-grade glioma treated in Slovenia in given period of time were included in study. Postoperatively they completed neuropsychological assessment consisting of Slovenian Verbal Learning Test, Slovenian Controlled Oral Word Association Test, Trail Making Test Part A and B and self-evaluation questionnaire. We analysed results (z-scores and dichotomized results) also according to IDH mutation and MGMT methylation. We examined differences between groups using T-test, Mann-Whitney U, χ² and Kendall's Tau tests.</p><p><strong>Results: </strong>Out of 275 patients in the cohort, we included 90. Forty-six percent of patients were unable to participate due to poor performance status and other conditions related to tumour. Patients with the IDH mutation were younger, with better performance status, larger proportions of grade III tumours and MGMT methylation. In this group cognitive functioning is significantly better in the domains of immediate recall, short delayed recall and delayed recall, and in the fields of executive functioning and recognition. There were no differences in cognitive functioning in regard to MGMT status. Grade III tumours were associated with more frequent MGMT methylation. Self-assessment proved week tool, associated only with immediate recall.</p><p><strong>Conclusions: </strong>We found no differences in cognitive functioning according to MGMT status, but cognition was better when IDH mutation was present. In a cohort study of patients with high-grade glioma, almost half were unable to participate in a study, which points to an overrepresentation of patients with better cognitive functioning in the research.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"201-210"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9764025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD56-positive diffuse large B-cell lymphoma: comprehensive analysis of clinical, pathological, and molecular characteristics with literature review.","authors":"Gorana Gasljevic,&nbsp;Lucka Boltezar,&nbsp;Srdjan Novakovic,&nbsp;Vita Setrajcic-Dragos,&nbsp;Barbara Jezersek-Novakovic,&nbsp;Veronika Kloboves-Prevodnik","doi":"10.2478/raon-2023-0016","DOIUrl":"https://doi.org/10.2478/raon-2023-0016","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. The expression of CD56 in DLBCL is highly unusual. Little is known about its incidence and clinical importance. So far, no genetic profiling was performed in CD56 positive DLBCL.</p><p><strong>Patients and methods: </strong>Tissue microarrays have been constructed, sectioned, and stained by H&E and immunohistochemistry for 229 patients with DLBCL diagnosed 2008-2017. For CD56 positive cases, clinical data was collected including age at diagnosis, stage of the disease, International Prognostic Index (IPI) score, treatment scheme and number of chemotherapy cycles, radiation therapy, treatment outcome, and possible relapse of the disease. Overall survival (OS) and progression-free survival (PFS) were calculated. For four patients, RNA was extracted and targeted RNA (cDNA) sequencing of 125 genes was performed with the Archer FusionPlex Lymphoma kit.</p><p><strong>Results: </strong>CD56 expression was found in 7 cases (3%). The intensity of expression varied from weak to moderate focal, to very intensive and diffuse. All patients had <i>de novo</i> DLBCL. The median age at the time of diagnosis was 54.5 years. Five of them were women and 2 males. According to the Hans algorithm, 6 patients had the germinal centre B cells (GBC) type and one non-GBC (activated B-cell [ABC]) type, double expressor. Genetic profiling of four patients according to Schmitz's classification showed that 1 case was of the BN2 subtype, 1 of EZB subtype, 2 were unclassified. The six treated patients reached a complete response and did not experience progression of the disease during the median follow-up period of 80.5 months.</p><p><strong>Conclusions: </strong>We report on one of the largest series of CD56+DLBCL with detailed clinicopathological data and for the first time described genetical findings in a limited number of patients. Our results show that CD56 expression is rare, but seems to be present in prognostic favourable subtypes of DLBCL not otherwise specified (NOS) as tested by immunohistochemical or genetic profiling.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"249-256"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9703689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients.","authors":"Zlatko Pravdic,&nbsp;Nada Suvajdzic Vukovic,&nbsp;Vladimir Gasic,&nbsp;Irena Marjanovic,&nbsp;Teodora Karan-Djurasevic,&nbsp;Sonja Pavlovic,&nbsp;Natasa Tosic","doi":"10.2478/raon-2023-0017","DOIUrl":"https://doi.org/10.2478/raon-2023-0017","url":null,"abstract":"<p><strong>Background: </strong>Deregulation of the apoptotic process underlies the pathogenesis of many cancers, including leukemia, but is also very important for the success of chemotherapy treatment. Therefore, the gene expression profile of main apoptotic factors, such as anti-apoptotic <i>BCL2</i> (B-cell lymphoma protein 2) and pro-apoptotic <i>BAX</i> (BCL2-associated X), as well as genes involved in the multi-drug resistance (<i>ABCB1</i>), could have significant impact on the prognosis and could be used as targets for specific therapy.</p><p><strong>Patients and methods: </strong>We analyzed the expression of <i>BCL2</i>, <i>BAX,</i> and <i>ABCB1</i> in bone-marrow samples collected at diagnosis from 51 adult patients with acute myeloid leukemia with normal karyotype (AML-NK) using real-time polymerase chain reaction method, and examined their prognostic potential.</p><p><strong>Results: </strong>Increased expression of <i>BCL2</i> (<i>BCL2</i> ⁺) was associated with the presence of chemoresistance (p = 0.024), while patients with low <i>BAX</i> expression were more prone to relapse (p = 0.047). Analysis of the combined effect of <i>BCL2</i> and <i>BAX</i> expression showed that 87% of patients with <i>BAX/BCL2</i> ^low status were resistant to therapy (p = 0.044). High expression of <i>ABCB1</i> was associated with <i>BCL2</i> ⁺ status (p < 0.001), and with absence <i>FLT3-ITD</i> mutations (p = 0.019).</p><p><strong>Conclusions: </strong>The present analysis of <i>BCL2</i>, <i>BAX,</i> and <i>ABCB1</i> gene expression profiles is the first study focusing solely on AML-NK patients. Preliminary results showed that patients with high <i>BCL2</i> expression are likely to experience resistance to chemotherapy, and may benefit from specific anti-BCL2 treatment. Further investigations conducted on a larger number of patients could elucidate actual prognostic significance of these genes in AML-NK patients.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"239-248"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9705607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of mean apparent diffusion coefficient (ADC) and maximal standard uptake value (SUVmax) evaluated by diffusion-weighted MRI and 18F-FDG-PET/CT in children with Hodgkin lymphoma: a feasibility study.","authors":"Nicolas Rosbach,&nbsp;Sebastian Fischer,&nbsp;Vitali Koch,&nbsp;Thomas J Vogl,&nbsp;Konrad Bochennek,&nbsp;Thomas Lehrnbecher,&nbsp;Scherwin Mahmoudi,&nbsp;Leon Grünewald,&nbsp;Frank Grünwald,&nbsp;Simon Bernatz","doi":"10.2478/raon-2023-0021","DOIUrl":"https://doi.org/10.2478/raon-2023-0021","url":null,"abstract":"<p><strong>Background: </strong>The objective was to analyse if magnetic resonance imaging (MRI) can act as a non-radiation exposure surrogate for (18)F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in children with histologically confirmed Hodgkin lymphoma (HL) before treatment. This was done by analysing a potential correlation between apparent diffusion coefficient (ADC) in MRI and the maximum standardized uptake value (SUVmax) in FDG-PET/CT.</p><p><strong>Patients and methods: </strong>Seventeen patients (six female, eleven male, median age: 16 years, range: 12-20 years) with histologically confirmed HL were retrospectively analysed. The patients underwent both MRI and (18)F-FDG PET/CT before the start of treatment. (18)F-FDG PET/CT data and correlating ADC maps in MRI were collected. For each HL-lesion two readers independently evaluated the SUVmax and correlating meanADC.</p><p><strong>Results: </strong>The seventeen patients had a total of 72 evaluable lesions of HL and there was no significant difference in the number of lesions between male and female patients (median male: 15, range: 12-19 years, median female: 17 range: 12-18 years, p = 0.021). The mean duration between MRI and PET/CT was 5.9 ± 5.3 days. The inter-reader agreement as assessed by the intraclass correlation coefficient (ICC) was excellent (ICC = 0.98, 95% CI: 0.97-0.99). The correlated SUVmax and meanADC of all 17 patients (ROIs n = 72) showed a strong negative correlation of -0.75 (95% CI: -0.84, - -0.63, p = 0.001). Analysis revealed a difference in the correlations of the examination fields. The correlated SUVmax and meanADC showed a strong correlation at neck and thoracal examinations (neck: -0.83, 95% CI: -0.93, - -0.63, p < 0.0001, thoracal: -0.82, 95% CI: -0.91, - -0.64, p < 0.0001) and a fair correlation at abdominal examinations of -0.62 (95% CI: -0.83, - -0.28, p = 0.001).</p><p><strong>Conclusions: </strong>SUVmax and meanADC showed a strong negative correlation in paediatric HL lesions. The assessment seemed robust according to inter-reader agreements. Our results suggest that ADC maps and meanADC have the potential to replace PET/CT in the analysis of disease activity in paediatric Hodgkin lymphoma patients. This may help reduce the number of PET/CT examinations and decrease radiation exposure to children.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"150-157"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-guided biopsies of unspecified suspect intrahepatic lesions: pre-procedure Lipiodol-marking improves the biopsy success rate.","authors":"Marcel Christian Langenbach,&nbsp;Thomas Joseph Vogl,&nbsp;Amelie Buchinger,&nbsp;Katrin Eichler,&nbsp;Jan-Erik Scholtz,&nbsp;Renate Hammerstingl,&nbsp;Tatjana Gruber-Rouh","doi":"10.2478/raon-2023-0024","DOIUrl":"https://doi.org/10.2478/raon-2023-0024","url":null,"abstract":"<p><strong>Background: </strong>While computed tomography (CT)-guided liver biopsies are commonly performed using unenhanced images, contrast-enhanced images are beneficial for challenging puncture pathways and lesion locations. This study aimed to evaluate the accuracy of CT-guided biopsies for intrahepatic lesions using unenhanced, intravenous (IV)-enhanced, or intra-arterial Lipiodol-marked CT for lesion marking.</p><p><strong>Patients and methods: </strong>Six-hundred-seven patients (men: 358 [59.0%], mean age 61 years; SD ±12.04) with suspect hepatic lesions and CT-guided liver biopsies were retrospectively evaluated. Successful biopsies were histopathological findings other than typical liver tissue or non-specific findings. Data was ascertained regarding the use of contrast medium for the biopsy-planning CT, unenhanced (group 1) <i>vs.</i> Lipiodol (group 2) <i>vs.</i> IV contrast (group 3). Technical success and influencing factors were insulated. Complications were noted. The results were analyzed using the Wilcoxon-Man-Whitney t-test, Chi-square test, and Spearman-Rho.</p><p><strong>Results: </strong>Overall lesion hitting rate was 73.1%, with significantly better rates using Lipiodol-marked lesions (79.3%) compared to group 1 (73.8%) and group 3 (65.2%) (p = 0.037). Smaller lesions (<20 mm diameter) benefited significantly from Lipiodol-marking with 71.2% successful biopsy rate compared to group 1 (65.5%) and group 3 (47.7%) (p = 0.021). Liver cirrhosis (p = 0.94) and entity of parenchymal lesions (p = 0.78) had no impact on the hitting rate between the groups. No major complications occurred during the interventions.</p><p><strong>Conclusions: </strong>Pre-biopsy Lipiodol marking of suspect hepatic lesions significantly increases the lesion-hitting rate and is especially beneficial for biopsy of smaller targets below 20 mm diameter. Further, Lipiodol marking is superior to IV contrast for non-visible lesions in unenhanced CT. Target lesion entity has no impact on the hitting rate.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"158-167"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9764023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ADC values as a biomarker of fetal brain maturation.","authors":"Lucija Kobal,&nbsp;Katarina Surlan Popovic,&nbsp;Jernej Avsenik,&nbsp;Tina Vipotnik Vesnaver","doi":"10.2478/raon-2023-0022","DOIUrl":"https://doi.org/10.2478/raon-2023-0022","url":null,"abstract":"<p><strong>Background: </strong>During the period of fetal development, myelination plays a key role and follows specific time and spatial sequences. The water content in the brain is inversely proportional to myelination - the more myelinated the brain, the lower the water content in it. The diffusion of water molecules can be quantitatively assessed using the apparent diffusion coefficient (ADC). We were interested in whether, by determining the ADC values, we could quantitatively evaluate the development of the fetal brain.</p><p><strong>Patients and methods: </strong>The study included 42 fetuses with gestational age 25 to 35 weeks. We manually selected 13 regions on diffusion-weighted images. Statistically significant differences between ADC values were checked using one-way analysis of variance and Tukey's post hoc test. The relationship between the ADC values and the gestational age of the fetuses was then assessed using linear regression.</p><p><strong>Results: </strong>The average gestational age of the fetuses was 29.8 ± 2.4 weeks. ADC values in the thalami, pons and cerebellum differed significantly among each other and from the ADC values in other brain regions. In the thalami, pons and cerebellum, linear regression showed a significant decrease in ADC values with increasing gestational age.</p><p><strong>Conclusions: </strong>ADC values change with the increasing gestational age of the fetus and differ among different brain regions. In the pons, cerebellum and thalami, the ADC coefficient could be used as a biomarker of fetal brain maturation since ADC values decrease linearly with increasing gestational age.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"178-183"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-stage hepatectomy in resection of colorectal liver metastases - a single-institution experience with case-control matching and review of the literature.","authors":"Spela Turk,&nbsp;Irena Plahuta,&nbsp;Tomislav Magdalenic,&nbsp;Tajda Spanring,&nbsp;Kevin Laufer,&nbsp;Zan Mavc,&nbsp;Stojan Potrc,&nbsp;Arpad Ivanecz","doi":"10.2478/raon-2023-0026","DOIUrl":"https://doi.org/10.2478/raon-2023-0026","url":null,"abstract":"<p><strong>Background: </strong>Two-stage hepatectomy (TSH) has been proposed for patients with bilateral liver tumours who have a high risk of posthepatectomy liver failure after one-stage hepatectomy (OSH). This study aimed to determine the outcomes of TSH for extensive bilateral colorectal liver metastases.</p><p><strong>Patients and methods: </strong>A retrospective review of a prospectively maintained database of liver resections for colorectal liver metastases was conducted. The TSH group was compared to the OSH group in terms of perioperative outcomes and survival. Case-control matching was performed.</p><p><strong>Results: </strong>A total of 632 consecutive liver resections for colorectal liver metastases were performed between 2000 and 2020. The study group (TSH group) consisted of 15 patients who completed TSH. The control group included 151 patients who underwent OSH. The case-control matching-OSH group consisted of 14 patients. The major morbidity and 90-day mortality rates were 40% and 13.3% in the TSH group, 20.5% and 4.6% in the OSH group and 28.6% and 7.1% in the case-control matching-OSH group, respectively. The recurrence-free survival, median overall survival, and 3- and 5-year survival rates were 5 months, 21 months, 33% and 13% in the TSH group; 11 months, 35 months, 49% and 27% in the OSH group; and 8 months, 23 months, 36% and 21%, respectively, in the case-control matching-OSH group, respectively.</p><p><strong>Conclusions: </strong>TSH used to be a favourable therapeutic choice in a select population of patients. Now, OSH should be preferred whenever feasible because it has lower morbidity and equivalent oncological outcomes to those of completed TSH.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"270-278"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in the quality of life of early breast cancer patients and comparison with the normative Slovenian population.","authors":"Cvetka Grasic Kuhar,&nbsp;Tjasa Gortnar Cepeda,&nbsp;Christian Kurzeder,&nbsp;Marcus Vetter","doi":"10.2478/raon-2023-0019","DOIUrl":"https://doi.org/10.2478/raon-2023-0019","url":null,"abstract":"<p><strong>Background: </strong>We aimed to identify changes in quality of life after breast cancer treatment and compare them with the normative population data for the Slovenian population.</p><p><strong>Patients and methods: </strong>A prospective, single-group, cohort design was used. A total of 102 early breast cancer patients treated with chemotherapy at the Institute of Oncology Ljubljana were included. Of those, 71% returned the questionnaires after one-year post-chemotherapy. The Slovenian versions of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ C30 and BR23 questionnaires were used. Primary outcomes were a comparison of global health status/quality of life (GHS) and C30 Summary Score (C30-SumSc) at baseline and one-year post-chemotherapy with the normative Slovenian population. The exploratory analysis evaluated the differences in symptoms and functional scales of QLQ C-30 and QLQ BR-23 between baseline and one-year post-chemotherapy.</p><p><strong>Results: </strong>At baseline and one-year post-chemotherapy, C30-SumSc of patients was lower than the predicted C30-SumSc from the normative Slovenian population by 2.6 points (p = 0.04) and 6.5 points (p < 0.001), resp. On the contrary, GHS was not statistically different from predicted either at baseline or after one year. Exploratory analysis revealed that one-year post-chemotherapy compared to the beginning of chemotherapy, patients had statistically significantly and clinically meaningful lower scores in body image and cognitive functioning, and increased symptom scores for pain, fatigue, and arm symptoms.</p><p><strong>Conclusions: </strong>The C30-SumSc is reduced one-year post-chemotherapy. Early interventions should be directed toward the prevention of the decline of cognitive functioning and body image, and to alleviate fatigue, pain, and arm symptoms.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 2","pages":"211-219"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}